ARDD 2025 Report Maps Nearest-Term Human Aging Interventions
The longevity field's most cited annual gathering just published its 2025 consensus report — and the emphasis has shifted hard from mechanisms to actionable clinical interventions. The message: the biology is mature enough to act on.
Explanation
The 12th Aging Research and Drug Discovery (ARDD) meeting brought together leading scientists to assess where the longevity field actually stands — not in theory, but in terms of what can be tested or prescribed today or in the near future. The resulting report, published in the journal Aging-US, is essentially a field-wide status update from the people closest to the data.
What makes this report notable is the framing. Previous ARDD outputs leaned heavily on mechanistic discovery — mapping the biology of aging. This one pivots toward translation: which interventions have enough evidence to move into humans, and what does a credible clinical pathway look like?
The report covers a broad stack of approaches — senolytics (drugs that clear out damaged "zombie" cells), metabolic reprogramming, epigenetic clocks as biomarkers, and lifestyle-based interventions with measurable biological impact. The recurring theme is that the gap between mouse models and human trials is narrowing, but regulatory and trial-design frameworks haven't kept pace.
Why care now? Because this kind of consensus document shapes funding priorities, clinical trial design, and — increasingly — what longevity-focused physicians actually prescribe off-label. It's a leading indicator of where the serious money and serious science move next.
The honest caveat: meeting reports are summaries of expert opinion, not primary data. The signal here is directional, not definitive. Watch for which specific interventions get named as trial-ready — those are the ones to track.
The 12th ARDD meeting report, published in Aging-US (Volume 18, April 2026), represents a meaningful inflection in how the field self-describes its maturity. The shift from mechanistic consensus to intervention-readiness framing is deliberate and worth taking seriously — ARDD has historically been a reliable leading indicator of where translational momentum concentrates.
Key thematic clusters in the report include: senolytic and senomorphic strategies (with dasatinib/quercetin and navitoclax pipelines still the reference points, but newer candidates gaining ground); partial epigenetic reprogramming (Yamanaka factor cycling and small-molecule proxies); NAD+ metabolism modulation; and multi-omic biological age clocks as surrogate endpoints for trials. The latter is arguably the most consequential near-term development — without validated aging biomarkers, powering human trials remains prohibitively expensive and slow.
The report also engages with the regulatory gap directly. Current FDA frameworks don't recognize "aging" as an indication, forcing trials into disease-specific proxies (TAME trial's metformin/cardiovascular framing being the canonical example). The ARDD consensus appears to push for geroscience-informed trial design as a discipline, not just a concept.
Prior art context: this is the 12th iteration of a report series that has tracked the field since the early 2010s. The progression from "hallmarks of aging" (López-Otín et al., 2013) to "interventions in humans" as the organizing frame reflects roughly a decade of compounding preclinical evidence finally demanding clinical accountability.
Open questions the report likely surfaces but cannot resolve: which biomarker composite best predicts all-cause mortality reduction in a 3–5 year trial window; whether combination interventions (e.g., senolytics + reprogramming) show synergy or interference in humans; and how to handle the enormous heterogeneity in biological age trajectories across populations.
The falsifier to watch: if the next 18 months of Phase II readouts from senolytic and reprogramming trials fail to show clean biomarker signal, the "actionable now" framing in this report will look premature.
Reality meter
Why this score?
Trust Layer Score basis
A detailed evidence breakdown is being added. For now, the score basis is the source list below and the reality meter above.
- 39 sources on file
- Avg trust 44/100
- Trust 40–95/100
Time horizon
Community read
Glossary
- senolytics
- Drugs or compounds designed to selectively eliminate senescent cells—cells that have stopped dividing but accumulate in tissues and contribute to aging and age-related diseases. Examples include dasatinib and quercetin.
- senomorphic strategies
- Therapeutic approaches that modify the behavior or function of senescent cells without necessarily destroying them, aiming to reduce their harmful effects on surrounding tissues.
- epigenetic reprogramming
- A process that reverses age-related changes in gene expression patterns by resetting chemical modifications on DNA and histone proteins, often using Yamanaka factors or small-molecule compounds to restore a more youthful cellular state.
- NAD+ metabolism modulation
- Therapeutic strategies that increase or optimize levels of NAD+ (nicotinamide adenine dinucleotide), a critical molecule in cellular energy production and stress response that naturally declines with age.
- biological age clocks
- Multi-omic biomarkers that measure aging at the molecular level by analyzing patterns across genes, proteins, and other biological molecules to estimate a person's biological age independent of chronological age.
- geroscience
- The scientific field that studies the biological mechanisms of aging and develops interventions to extend healthspan—the period of life spent in good health—rather than just lifespan.
What's your read?
Your read shapes future topic weighting.
Your vote feeds topic weights, community direction and future prioritisation. Open community direction
Sources
- Tier 3 Global experts highlight path toward actionable interventions in human aging
- Tier 3 Longevity Science Is Overhyped. But This Research Really Could Change Humanity.
- Tier 3 11 Rising Stars Shaping the Future of Longevity - Business Insider
- Tier 3 Anti Aging Research 2024: New For 2025 - Liv Hospital
- Tier 3 Scientists boost lifespan by 70% in elderly male mice using simple drug combo | ScienceDaily
- Tier 3 Next gen cancer drug shows surprising anti aging power | ScienceDaily
- Tier 3 The Future of Longevity: Innovations in Aging Research - IMJ Health Blog
- Tier 3 A Scientist Says Humans Will Stop Aging by 2029, Here's the Technology That Could Make It Real
- Tier 3 Healthy Aging News -- ScienceDaily
- Tier 3 A cheap drug used by longevity enthusiasts may have a surprising impact on exercise
- Tier 3 A long and ongoing look at the secrets of human longevity and healthy aging | ScienceDaily
- Tier 3 This method to reverse cellular aging is about to be tested in humans | Scientific American
- Tier 1 This method to reverse cellular ageing is about to be tested in humans
- Tier 3 A hidden cellular cleanup trick could reverse aging | ScienceDaily
- Tier 3 Timeline of aging research - Wikipedia
- Tier 3 Scientists may have found how to reverse memory loss in aging brains | ScienceDaily
- Tier 3 Scientists reversed brain aging and memory loss in mice | ScienceDaily
- Tier 3 New nasal spray reverses brain aging while restoring memory, giving new hope to people with dementia
- Tier 1 Daily briefing: A treatment to reverse cellular ageing is about to be tested in people
- Tier 3 Life Extension Treatments: A New Era in Anti-Aging (2026)
- Tier 3 Clinical trial for Longevity drug meets goal of enrolling 1000 dogs | dvm360
- Tier 3 Home lifespan | Lifespan Research Institute
- Tier 3 FDA determines drug for lifespan extension in large dogs to have a Reasonable Expectation of Effectiveness | dvm360
- Tier 3 Seragon Publishes Record-Breaking SRN-901 Longevity Data, Demonstrating 33% Lifespan Extension in Mice
- Tier 3 Second drug for canine healthy lifespan extension receives FDA support | dvm360
- Tier 3 Can aging be slowed? Some academic scientists think so | AAMC
- Tier 3 Reconsidering GLYNAC: What the Evidence Actually Says About Glycine, NAC, Reversing Aging, and Life Extension - New Life Longevity
- Tier 1 Cardiovascular ageing: hallmarks, signaling pathways, diseases and therapeutic targets | Signal Transduction and Targeted Therapy
- Tier 3 Serum protein profiling reveals hallmark-level aging trajectories and strain-specific resilience in CB6F1J and C57BL/6J male mice | bioRxiv
- Tier 3 dsm-firmenich unveils science-backed longevity innovations at Vitafoods Europe 2026
- Tier 3 Organelle resilience as a comparative blueprint for longevity | EMBO Molecular Medicine | Springer Nature Link
- Tier 3 The Hallmarks of Aging and Senescence
- Tier 3 The 14 Hallmarks of Aging: How NAD+ Plays a Role in Every Hallmark
- Tier 3 The Hallmarks of Aging
- Tier 3 Supplement industry demands human trials to prove ageless vitality science
- Tier 3 Top 10 Longevity Peptides for Anti-Aging Research in 2026 - Loti Labs Resources
- Tier 3 The expert on 'super aging' breaks down the science — and grift — in anti-aging : NPR
- Tier 3 A Death-Defying Superpower in This Centenarian’s Blood is Keeping Her Healthy, Scientists Discovered
- Tier 3 The Guide to Longevity Checkups in 2026: What to Test & Why
Optional Submit a prediction Optional: add your prediction on the core question if you like.
Prediction
Will at least one intervention highlighted in the ARDD 2025 report receive a formal regulatory trial designation or approval for an aging-related indication by end of 2027?